Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

prnewswire

Mar 17

SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.

Following Ribo's success of the RiboGalSTAR™ targeting liver specific genes with seven programs in clinical and two major global collaborations and licensing deals valued more than USD 6B, Ribo now continues its innovation journey towards the ex-hepatic space enabled by its proprietary delivery technology platform RiboPepSTAR™. The RiboPepSTAR™ platform enables targeted siRNA delivery to multiple critical organs beyond the liver. By using the platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.

In addition to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.

SOURCE Suzhou Ribo Life Science Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620215414"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620215414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620215414?lang=en_US&edition=fundamental","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","is_english":true,"pubTime":"2026-03-17 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620215414","market":"other","top_or_hot":-1,"title":"Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference","media":"prnewswire","content":"<html><body><div>\n<div>\n<p><span>SUZHOU, China and MÖLNDALS, Sweden</span>, <span>March 17, 2026</span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (\"Ribo\" or \"the Company\", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.</p>\n<p>Following Ribo's success of the RiboGalSTAR™ targeting liver specific genes with seven programs in clinical and two major global collaborations and licensing deals valued more than USD <span>6B</span>, Ribo now continues its innovation journey towards the ex-hepatic space enabled by its proprietary delivery technology platform RiboPepSTAR™. The RiboPepSTAR™ platform enables targeted siRNA delivery to multiple critical organs beyond the liver. By using the platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.</p>\n<p>In addition to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.</p>\n<p>SOURCE Suzhou Ribo Life Science Co., Ltd.</p>\n<img src=\"https://rt.prnewswire.com/rt.gif?NewsItemId=AE10679&amp;Transmission_Id=202603162300PR_NEWS_ASPR_____AE10679&amp;DateId=20260316\"/>\n</div>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo to present ex-hepatic delivery data at RNA Leaders Europe Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1055060725\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">prnewswire </p>\n<p class=\"h-time\">2026-03-17 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<p><span>SUZHOU, China and MÖLNDALS, Sweden</span>, <span>March 17, 2026</span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (\"Ribo\" or \"the Company\", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.</p>\n<p>Following Ribo's success of the RiboGalSTAR™ targeting liver specific genes with seven programs in clinical and two major global collaborations and licensing deals valued more than USD <span>6B</span>, Ribo now continues its innovation journey towards the ex-hepatic space enabled by its proprietary delivery technology platform RiboPepSTAR™. The RiboPepSTAR™ platform enables targeted siRNA delivery to multiple critical organs beyond the liver. By using the platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.</p>\n<p>In addition to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.</p>\n<p>SOURCE Suzhou Ribo Life Science Co., Ltd.</p>\n<img src=\"https://rt.prnewswire.com/rt.gif?NewsItemId=AE10679&amp;Transmission_Id=202603162300PR_NEWS_ASPR_____AE10679&amp;DateId=20260316\"/>\n</div>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-to-present-ex-hepatic-delivery-data-at-rna-leaders-europe-conference-302715382.html","article_id":"2620215414","we_media_id":"1055060725","thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620215414","pubTimestamp":1773716400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"prnewswire","introduction":"prnewswire","home_visible":1,"id":"1055060725","head_image":"https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c"},"summary":"SUZHOU, China and MLNDALS, Sweden, March 17, 2026 /PRNewswire/ --Suzhou Ribo Life Science Co., Ltd.  has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.Following Ribo's success of the RiboGalSTAR targeting liver specific genes with seven programs in clinical and two major global collaborations and licensing deals valued more than USD 6B, Ribo now continues its innovation journey towards the ex-hepatic space enabled by its proprietary delivery technology platform RiboPepSTAR. The RiboPepSTAR platform enables targeted siRNA delivery to multiple critical organs beyond the liver. By using the platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.In addition to kidney, more targeted drug candidates are under pre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","RNA":"Atrium Therapeutics"},"translate_title":"Ribo将在RNA Leaders欧洲会议上展示肝外输送数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1.5},"content_text":"SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (\"Ribo\" or \"the Company\", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.\nFollowing Ribo's success of the RiboGalSTAR™ targeting liver specific genes with seven programs in clinical and two major global collaborations and licensing deals valued more than USD 6B, Ribo now continues its innovation journey towards the ex-hepatic space enabled by its proprietary delivery technology platform RiboPepSTAR™. The RiboPepSTAR™ platform enables targeted siRNA delivery to multiple critical organs beyond the liver. By using the platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.\nIn addition to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.\nSOURCE Suzhou Ribo Life Science Co., Ltd.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}